Custopharm, Inc. v. Exela Pharma Sciences, LLC

District Court, S.D. California·Decided February 4, 2022·No. 3:20-cv-01587·Unknown

Opinion

CUSTOPHARM, INC., a Texas Case No.: 20-cv-01587-AJB-DEB Corporation, ORDER DENYING DEFENDANT’S Plaintiff, MOTION TO DISMISS THE FIRST AMENDED COMPLAINT v. (Doc. No. 17) EXELA PHARMA SCIENCES, LLC, a Delaware Limited Liability Company,

Defendant. Pending before the Court is Exela Pharma Sciences, LLC’s (“Defendant”) Motion to Dismiss CustoPharm, Inc.’s (“Plaintiff”) First Amended Complaint (“FAC”). (Doc. No. 17.) Plaintiff filed an opposition to the motion (Doc. No. 27), and Defendant filed a reply (Doc. No. 28). For the reasons set forth below, the Court DENIES Defendant’s motion. This action stems from an alleged breach of contract. On or about May 19, 2009, Plaintiff entered into a written referral fee agreement (“Referral Agreement”) with Defendant. (Doc. No. 24 ¶ 6.) Under the Referral Agreement, Plaintiff agreed to refer business to Defendant “for the production of pre-launch clinical trial materials and production of development and commercial drug products[.]” (Id.) In turn, Defendant promised to (1) “keep any such information disclosed by [Plaintiff] confidential and not disclose such information to any third party, or use such information for their own benefit to start a new project” and (2) “pay [Plaintiff a] five percent (5%) commission on all payments received from any referral that resulted in a drug product being manufactured by [Defendant].” (Id. ¶ 8.) The commission included “any payments received from the referral, including payments received from R & D work, pre-launch development activities, commercial drug produce [sic] manufacturing and royalties from referred business.” (Id. ¶ 9.) Commission payments were due within thirty days of Defendant receiving payments from the referred business, with a one and a half percent (1.5%) late fee. (Id.) At the time of the Referral Agreement, “there were six (6) companies that [Plaintiff] identified and [Defendant] acknowledged had been referred pursuant to the terms of the Referral Agreement.” (Id. ¶ 10.) Since the parties executed the Referral Agreement, the number of referred companies “grew to at least eleven (11) companies.” (Id.) “The Referral Agreement allowed either party to terminate the Referral Agreement ‘with six months written notice with all existing business surviving termination[.]’” (Id. ¶ 11 (quoting the Referral Agreement).) On or about April 19, 2012, Defendant provided written notice to terminate the Referral Agreement and proposed new terms and obligations, including revising the survivability provision. (Id. ¶ 12.) Plaintiff accepted only the termination notice and never agreed to the proposed new terms. (Id. ¶ 13.) Defendant’s termination notice became effective on October 19, 2012. (Id.) After termination, Plaintiff claims Defendant made two referral payments under the Referral Agreement in 2013 and 2014. (Id. ¶ 15.) From 2015 to 2020, Plaintiff inquired with Defendant if Defendant “was conducting business with any of the eleven (11) companies listed in the Referral Agreement and whether any commissions were owed to [Plaintiff].” (Id.) Plaintiff claims Defendant “never identified any such business and never disclosed that, in fact, it had received revenues” from some of the eleven companies. (Id.) Plaintiff further alleges there was no way to verify Defendant’s information and relied on Defendant to provide truthful and accurate information. (Id. ¶ 16.) Plaintiff alleges that it first learned that Defendant was conducting business with the referred companies and owed commissions to Plaintiff in June 2020, through a third-party. (Id. ¶ 17.)1 Plaintiff thereafter contacted Defendant, and Defendant allegedly provided Plaintiff a spreadsheet indicating “over $1.1 million was earned and owed in commissions under the Referral Agreement since 2015.” (Id. ¶ 18.) Plaintiff demanded payment but Defendant allegedly “refused claiming some newly created offset as an excuse not to pay.” (Id. ¶ 19.) The FAC asserts claims for (1) breach of contract, (2) accounting, and (3) declaratory relief. The instant motion to dismiss the FAC pursuant to Federal Rule of Civil Procedure (“Rule”) 12(b)(6) follows. A Rule 12(b)(6) motion to dismiss tests the legal sufficiency of the complaint. Navarro v. Block, 250 F.3d 729, 732 (9th Cir. 2001). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). Facial plausibility is satisfied “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. The plausibility standard is not a probability requirement but rather “asks for more than a sheer possibility that a defendant has acted unlawfully.” Id. To determine the sufficiency of the complaint, the court must assume the truth of all factual allegations therein and construe them in the light most favorable to the plaintiff. Cahill v. Liberty Mut. Ins. Co., 80 F.3d 336, 337–38 (9th Cir. 1996). This tenet, however, does not apply to legal conclusions. Iqbal, 556 U.S. at 678. “Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice.” Id.; Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007). “[W]here the well-pleaded facts do not permit the court to infer more than the mere possibility of misconduct,” the complaint is subject to dismissal. Iqbal, 556 U.S. at 679.

Free access — add to your briefcase to read the full text and ask questions with AI

Custopharm, Inc. v. Exela Pharma Sciences, LLC, (S.D. Cal. 2022).

Custopharm, Inc. v. Exela Pharma Sciences, LLC (Custopharm, Inc. v. Exela Pharma Sciences, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Reno v. Catholic Social Services, Inc.
509 U.S. 43 (Supreme Court, 1993)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. State Of Washington
759 F.2d 1353 (Ninth Circuit, 1985)
Aryeh v. Canon Business Solutions, Inc.
292 P.3d 871 (California Supreme Court, 2013)
Oasis West Realty v. Goldman
250 P.3d 1115 (California Supreme Court, 2011)
Niles v. Louis H. Rapoport & Sons, Inc.
128 P.2d 50 (California Court of Appeal, 1942)
Von Saher v. Norton Simon Museum of Art at Pasadena
592 F.3d 954 (Ninth Circuit, 2010)
April Enterprises, Inc. v. KTTV
147 Cal. App. 3d 805 (California Court of Appeal, 1983)
Teselle v. McLoughlin
173 Cal. App. 4th 156 (California Court of Appeal, 2009)
Gryczman v. 4550 Pico Partners, Ltd.
131 Cal. Rptr. 2d 680 (California Court of Appeal, 2003)
Tsemetzin v. Coast Federal Savings & Loan Ass'n
57 Cal. App. 4th 1334 (California Court of Appeal, 1997)
Perez-Encinas v. Amerus Life Insurance
468 F. Supp. 2d 1127 (N.D. California, 2006)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
Snyder v. California Insurance Guarantee Assn.
229 Cal. App. 4th 1196 (California Court of Appeal, 2014)
Navarro v. Block
250 F.3d 729 (Ninth Circuit, 2001)